Related Experiment Video
Updated: May 21, 2026

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
Published on: April 13, 2015
Gemcitabine causes telomere attrition by stabilizing TRF2.
Chih-Hao Su1, Wei-Chih Chu, Keng-Hsin Lan
1Institute of Biochemistry and Molecular Biology, National Yang-Ming University, No. 155 Sec 2 Linong St., Taipei, Taiwan.
Gemcitabine, an anti-cancer drug, shortens telomeres by stabilizing TRF2, leading to DNA damage and tumor growth inhibition. This novel mechanism reveals a new way gemcitabine fights cancer beyond DNA synthesis inhibition.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gemcitabine is a key chemotherapy drug for solid tumors.
- Its primary mechanism involves DNA synthesis inhibition.
- The role of gemcitabine in tumor growth inhibition beyond DNA incorporation is unclear.
Purpose of the Study:
- To investigate novel anti-tumor mechanisms of gemcitabine.
- To explore gemcitabine's effect on telomeres and associated proteins.
Main Methods:
- Cellular assays to assess gemcitabine's impact on telomere length.
- Analysis of TRF2 protein stabilization and its interaction with XPF/ERCC1.
- Investigating telomere shortening induced by TRF2 overexpression.
Main Results:
- Gemcitabine induces telomere shortening by stabilizing TRF2.
- Stabilized TRF2 is essential for XPF-dependent telomere loss.
- Overexpression of TRF2 alone also causes telomere shortening and associates with XPF/ERCC1.
Conclusions:
- Gemcitabine exhibits anti-tumor activity through a novel mechanism involving telomere shortening.
- TRF2 stabilization and subsequent XPF-dependent telomere loss are key components of this pathway.
- This finding expands our understanding of gemcitabine's therapeutic effects in cancer treatment.
Related Concept Videos
Telomeres and Telomerase
Telomeres and Telomerase
Replicative Cell Senescence
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Treatment Resistant Cancers

